Mogamulizumab, a defossilized humanized anti-CCR4 monoclonal antibody, has been shown to effectively treat T-cell lymphomas by enhancing antibody-dependent cell-mediated cytotoxicity (ADCC) [34]. Here, CCR4 is linked to T-cell non-Hodgkin lymphoma.